Fig. 4.

PDZ1i treatment impairs EGFRvIII and FAK signaling as well as EGFRvIII–MDA-9 interaction. (A) Immunoblot analysis showing expression of mutated EGFR in U87 or U87-EGFRvIII cells. (B) Cells were treated with either DMSO or PDZ1i 2 h before radiation. Cells were subsequently seeded on fibronectin-coated plates and cell lysates were collected after 1 h and analyzed for protein expression. (C) Lysates from cells treated with and without radiation or PDZ1i as indicated were analyzed via immunoprecipitation (IP). Anti–MDA-9 (Top) and anti-EGFR (Bottom) were used to pull down associated complexes, and Western blotting (WB) used the indicated antibodies. (Left) IgG and control input samples.